Strafford will be offering a webinar/teleconference entitled "Navigating Section 112(a) Enablement and Written Description -- Withstanding 112(a) Rejections and Attacks on Patent Validity and Patentability" on June 4, 2015 from 1:00 to 2:30 pm (EDT). Rekha Bansal, Sr. Director of IP, Principia Biopharma; and Thomas L. Irving, Dr. Jill K. MacAlpine, Deborah M. Herzfeld, and Cory C. Bell of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel on leveraging Federal Circuit and PTAB decisions and offer strategies to overcome § 112 challenges or, in the context of AIA's post grant proceedings how to utilize the extant § 112 precedent to break chains of date benefit or mount substantive § 112 attacks in PGR. The webinar will review the following questions:
• What judicial lessons can patent counsel draw when drafting claims and making during ex parte prosecution arguments at the USPTO of written description support and enablement for those claims?
• What steps can counsel for patentees take to meet the written description requirement and withstand invalidity/unpatentability challenges based on written description and enablement, whether at the PTAB, in expert prosecution or in district court litigation?
• What steps can counsel for alleged infringers and/or clients concerned about freedom to operate take to utilize § 112 to make challenges to date benefit/priority in IPRS and to do the same, as well as make substantive § 112 challenges in PRGs?
The registration fee for the webinar is $297 ($362 for registration and CLE processing). Those registering by May 8, 2015 will receive a $50 discount. Those interested in registering for the webinar, can do so here.
Comments